School of Medicine
Showing 1-10 of 62 Results
Professor of Pediatrics (Stem Cell Transplantation) and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated unequivocally that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program is focused on using genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, as well as conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
Professor of Medicine, Emeritus
Current Research and Scholarly Interests Retired
David Magnus, Ph.D.
Thomas A. Raffin Professor in Medicine and Biomedical Ethics, Professor (Teaching) of Medicine (General Medical Disciplines) and, by courtesy, of Bioengineering
Current Research and Scholarly Interests Genetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Bio Clinical Focus: Cardiovascular Medicine
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine
Clinical Associate Professor, Medicine - General Medical Disciplines
Current Research and Scholarly Interests As Associate Chief of Primary Care, I lead a team who are innovating in primary health care to empower patients and health care providers which can serve as a model of primary care in the future. Related to this work, I am a Visiting Associate Professor at the Aga Khan University East Africa and a lead consultant for the Integrated Primary Health Care Program which assesses strategies that lead to a better integrated primary health care system in a rural Kenya.